Common Equity: The sum of all common equity items.
Allergy Therapeutics (AGYTF) had Common Equity of $-9.16M for the most recently reported fiscal quarter, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$53.99M |
|
$21.40M |
|
$39.45M |
|
$93.44M |
|
$33.84M |
|
$54.50M |
|
$68.75M |
|
$102.59M |
|
|
Common Equity |
$-9.16M |
$-14.94M |
|
$-9.16M |
|
-- |
|
| Cash Flow Statement Financials | |
$-9.87M |
|
$-1.81M |
|
$22.76M |
|
$16.54M |
|
$27.76M |
|
$11.22M |
|
$-0.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|